Clinical Trials in Los Angeles

Showing 141-160 of 8,055 trials

PRISM Intervention Study

NCT03883139

This research study, Personalized, Responsive Intervention Sequences for Minimally Verbal Children with Autism (PRISM), is designed to maximize language outcomes for limited-language preschoolers, thereby lowering the risk of being classified as "minimally verbal" at age 6, by empirically developing a two-stage, 20-week adaptive intervention approach in a real world community settings. If found efficacious, the adaptive intervention design will capitalize on the heterogeneity and evolving status of children with ASD by providing the best intervention (DTT, JASPER and CET) for children who need it (leading to individualized sequences of intervention), only when it is needed (potentially reducing burden on children).

Autism Spectrum Disorder

University of California, Los Angeles140 participantsStarted Mar 2021

Los Angeles, California, United States • Rochester, New York, United States • Eugene, Oregon, United States

RECRUITINGPHASE1/PHASE2< 1 mile

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

NCT04065399

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.

Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMixed Lineage Acute Leukemia+2 more

Syndax Pharmaceuticals447 participantsStarted Nov 2019

Duarte, California, United States • Los Angeles, California, United States • Palo Alto, California, United States +54 more locations

PRISM Intervention Study

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Find Trials by Condition in Los Angeles

Study of DF1001 in Patients With Advanced Solid Tumors

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

A Study of Ponsegromab in People With Heart Failure

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

The CONFORM Pivotal Trial

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

A Study of DF6002 Alone and in Combination With Nivolumab

A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors

Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

Venclose digiRF System Post Market Study

A Study of ASP1002 in Adults for Treatment of Solid Tumors

Study to Evaluate the Clinical Safety and Performance of the CorNeat KPro for Treatment of Corneal Blindness